- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00353366
To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination
23 de febrero de 2021 actualizado por: GlaxoSmithKline
Open, Multicentric, Post-marketing Surveillance Study to Evaluate Safety and Reactogenicity of GSK Bio's Live Attenuated Oral Human Rotavirus (HRV) Vaccine, Rotarix When Administered According to Prescribing Information, in Filipino Subjects Aged at Least 6 Weeks of Age at the Time of First Vaccination
GSK has submitted a registration file for its live attenuated oral human rotavirus (HRV) vaccine in several countries.
In view of its registration in the Philippines, the present study will collect data on the safety of the vaccine in the local target population as per the Bureau of Food and Drugs Directive.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Descripción detallada
The protocol was amended to reflect a change in the prescribing information.
The age of the infants was changed from 6 - 14 weeks to at least 6 weeks at the time of the first vaccination.
This protocol posting has been amended in order to comply with FDA AA.
Tipo de estudio
De observación
Inscripción (Actual)
1439
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
-
Alabang, Muntinlupa City, Filipinas, 1780
- GSK Investigational Site
-
Binangonan, Rizal, Filipinas
- GSK Investigational Site
-
Cainta, Rizal, Filipinas
- GSK Investigational Site
-
Gen. Trias, Cavite, Filipinas
- GSK Investigational Site
-
Imus, Cavite, Filipinas
- GSK Investigational Site
-
Los Banos, Laguna, Filipinas, 4027
- GSK Investigational Site
-
Makati City, Filipinas
- GSK Investigational Site
-
Manila, Filipinas, 1000
- GSK Investigational Site
-
Manila, Filipinas
- GSK Investigational Site
-
Maybunga, Pasig City, Filipinas
- GSK Investigational Site
-
Muntinlupa City, Filipinas, 1780
- GSK Investigational Site
-
Pasay City, Filipinas
- GSK Investigational Site
-
Pasig City, Metro Manila, Filipinas, 1600
- GSK Investigational Site
-
Quezon City, Filipinas, 1113
- GSK Investigational Site
-
Quezon City, Filipinas
- GSK Investigational Site
-
Quezon City, Filipinas, 1102
- GSK Investigational Site
-
Talaba IV, Bacoor, Cavite, Filipinas
- GSK Investigational Site
-
Taytay, Rizal, Filipinas
- GSK Investigational Site
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
1 mes a 5 meses (Niño)
Acepta Voluntarios Saludables
Sí
Géneros elegibles para el estudio
Todos
Método de muestreo
Muestra no probabilística
Población de estudio
Filipino subjects aged at least 6 weeks at the time of first vaccination
Descripción
Inclusion Criteria:
- Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits) should be enrolled in the study.
- A Filipino male or female aged at least 6 weeks at the time of the first vaccination.
- Written informed consent obtained from the parent or guardian of the subject.
Exclusion Criteria:
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- Any history of chronic gastrointestinal disease including any uncorrected congenital malformation of the GI tract.
- Any contraindications as stated in the Prescribing Information.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Cohort Group
Subjects received two oral doses of the Rotarix vaccine at the age of 6 weeks
|
Two doses of the oral vaccine
Safety evaluation: recording of adverse events by using diary cards and by non-leading questioning.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Subjects Reporting Grade 2 or 3 Symptoms (Fever, Vomiting or Diarrhea).
Periodo de tiempo: During the 15-day (Days 0-14) solicited follow-up period after each vaccine dose (Dose 1 and Dose 2).
|
Grade 2 or 3 symptoms assessed include fever, vomiting and diarrhea.
Grade 2 fever was defined as axillary temperature above 38.0
degrees Celsius (°C) and below or equal to 39.0°C or rectal temperature above 38.5°C
and below or equal to 39.5°C.
Grade 3 fever was defined as axillary temperature above 39.0°C.
Grade 2 vomiting was defined as 2 episodes of vomiting per day.
Grade 3 vomiting was defined as at least 3 episodes of vomiting per day.
Grade 2 diarrhea was defined as 4-5 looser than normal stools per day.
Grade 3 diarrhea was defined as at least 6 looser than normal stools per day.
|
During the 15-day (Days 0-14) solicited follow-up period after each vaccine dose (Dose 1 and Dose 2).
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms.
Periodo de tiempo: During the 15-day solicited follow-up period (Day 0 to Day 14) after each vaccine dose (Dose 1 and Dose 2).
|
Solicited symptoms assessed included cough, diarrhea, fever, irritability, loss of appetite and vomiting.
Any = Any reports of the specified symptom irrespective of intensity grade and relationship to vaccination.
Grade 3 symptom: symptom that prevented normal activity.
Grade 3 loss of appetite = not eating at all, grade 3 fever = axillary temperature > 39.0°C, grade 3 vomiting = ≥ 3 episodes of vomiting/day and grade 3 diarrhea = ≥ 6 looser than normal stools/day.
Related = symptom assessed by the investigator as causally related to the vaccination regardless of intensity grade.
|
During the 15-day solicited follow-up period (Day 0 to Day 14) after each vaccine dose (Dose 1 and Dose 2).
|
|
Number of Subjects Reporting Unsolicited Adverse Events (AE)
Periodo de tiempo: During the 31-day follow-up period (Day 0 to Day 30) after any vaccine dose.
|
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Any was defined as an adverse event (AE) reported in addition to those solicited during the clinical study.
Any solicited symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.
|
During the 31-day follow-up period (Day 0 to Day 30) after any vaccine dose.
|
|
Number of Subjects Reporting Serious Adverse Events (SAE)
Periodo de tiempo: Throughout the study period (Day 0 to one month post-Dose 2).
|
Serious adverse events (SAEs) assessed include medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject.
|
Throughout the study period (Day 0 to one month post-Dose 2).
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
16 de noviembre de 2006
Finalización primaria (Actual)
31 de marzo de 2010
Finalización del estudio (Actual)
17 de julio de 2010
Fechas de registro del estudio
Enviado por primera vez
17 de julio de 2006
Primero enviado que cumplió con los criterios de control de calidad
17 de julio de 2006
Publicado por primera vez (Estimar)
18 de julio de 2006
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
16 de marzo de 2021
Última actualización enviada que cumplió con los criterios de control de calidad
23 de febrero de 2021
Última verificación
1 de febrero de 2021
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 103366
- 2012-004039-21 (Número EudraCT)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .